Regulatory approval

Published by the Health Service Executive. Approved

In combination with chemotherapy for induction treatment of previously untreated or relapsed/ refractory CD 20 positive patients with follicular lymphoma.

This is written in the approval document.

Reimbursement

Hospital

Citation

riTUXimab 375 mg/m2 Combination Therapy-21 day, 2025, version number 2a, NCCP National SACT Regimen, NCCP, viewed 26/03/2026, https://healthservice.hse.ie/documents/6642/542_v2a_riTUXimab_375_mgm2_CombinationTherapy.pdf

View API

Therapeutic response

Precision oncology relationships for therapeutic response derived from this regulatory approval.

Organizations Biomarkers Cancer types Therapies
HSE (1) CD20 + Follicular Lymphoma Cyclophosphamide, Prednisolone, Rituximab, Vincristine
HSE (1) CD20 + Follicular Lymphoma Cyclophosphamide, Doxorubicin, Prednisolone, Rituximab, Vincristine
HSE (1) CD20 + Follicular Lymphoma Chlorambucil, Mitoxantrone, Prednisolone, Rituximab
HSE (1) CD20 + Follicular Lymphoma Cyclophosphamide, Doxorubicin, Etoposide, Interferon Alpha, Prednisolone, Rituximab